{"id":"W3004987220","doi":"10.1200/jco.2020.38.4_suppl.478","title":"Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Tolerability; Ipilimumab; Hepatocellular carcinoma; Sorafenib; Mallinckrodt; Bristol-Myers; Oncology; Gastroenterology; Adverse effect; Cancer; Immunotherapy; Family medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005646701,0.0003993147,0.0007569849,0.0001999105,0.0001577712,0.0005189548,0.0002946185,0.0003219748,0.002924609],"category_scores_gemma":[0.0004811899,0.0001946432,0.001096919,0.0002886631,0.0002430221,0.0003187529,0.0002074596,0.001182593,0.0004694419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008973001,"about_ca_system_score_gemma":0.0006199421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001205144,"about_ca_topic_score_gemma":0.004840471,"domain_scores_codex":[0.9998606,0.00005809823,0.00001048784,0.00002596028,0.00001769709,0.00002710048],"domain_scores_gemma":[0.9997566,0.00004558617,0.00006327027,0.0000180414,0.00001537449,0.0001011295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6388984,0.01654053,0.02046732,0.002267231,0.003565066,0.0002514388,0.0001980148,0.00413968,0.01976526,0.0002594249,0.01201764,0.2816299],"study_design_scores_gemma":[0.466778,0.3937257,0.1029093,0.0003200584,0.006192544,0.0009252967,0.0001759405,0.003633189,0.006388232,0.0005366278,0.01833043,0.00008466891],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986632,0.0080473,0.000257458,0.000404071,0.00009995232,0.0005613288,0.001591688,0.00004954572,0.002356497],"genre_scores_gemma":[0.9908078,0.003591482,0.0005732268,0.0006127692,0.00006918106,0.0004484795,0.002309362,0.00001130713,0.00157632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002924609,"threshold_uncertainty_score":0.009783804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1409398227308897,"score_gpt":0.3533036802127839,"score_spread":0.2123638574818942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}